B-Cell Malignancies Clinical Trial
Official title:
A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib, ruxolitinib, or ibrutinib to participants from Incyte-sponsored studies of parsaclisib.
The purpose of this study is to provide continued use of parsaclisib as monotherapy or in combination with itacitinib, ruxolitinib, or ibrutinib to participants who are currently enrolled in an Incyte-sponsored study and receiving the same treatment, who have at least stable disease, who are obtaining clinical benefit (in the opinion of the investigator) on the current study treatment, as defined by the parent Protocol, and who are unable to access parsaclisib as monotherapy or in combination with itacitinib, ruxolitinib, or ibrutinib outside a clinical study. Participants will continue on the same dose and schedule as the ones being administered in the Incyte-sponsored parent Protocol at the time of the rollover. The study will collect and assess safety information with regards to AEs. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02343120 -
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT02018861 -
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
|
Phase 1/Phase 2 | |
| Terminated |
NCT03701438 -
Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib
|
||
| Completed |
NCT02327078 -
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
|
Phase 1/Phase 2 | |
| Completed |
NCT04551963 -
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT05683717 -
A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
|
Phase 1 | |
| Completed |
NCT01775631 -
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
|
Phase 1 | |
| Active, not recruiting |
NCT01905813 -
Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT05275504 -
Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT02457598 -
Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT03050190 -
A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03125577 -
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04170283 -
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
|
Phase 3 | |
| Not yet recruiting |
NCT03642496 -
Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies
|
Early Phase 1 | |
| Completed |
NCT00983619 -
A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies
|
Phase 1/Phase 2 |